Imagine trying to find a rare medicine in the ocean, but you can't just keep harvesting wild sponges and seaweed without destroying the reef. This project creates a 'recipe' to grow these sea creatures in a lab by mimicking their natural partnerships with bacteria. It's like building a tiny, controlled underwater farm to produce high-value ingredients without touching the ocean.
High-value marine molecules are too complex for chemical synthesis and too rare for sustainable wild harvesting. There is a critical lack of controlled lab-growing infrastructure to supply these to the pharmaceutical and cosmetic industries.
The project is building synthetic consortia of host and microbial cells and green isolation processes for terpenoids and alkaloids.
If you are a drug discovery firm dealing with the difficulty of sourcing complex marine alkaloids for new medicines — this project developed new chassis cells and cultivation methods that provide a stable, sustainable supply of these bioactives.
If you are a skincare brand dealing with the instability of wild-harvested seaweed terpenoids for anti-aging products — this project developed green downstream processes to isolate these compounds reliably in a lab setting.
If you are a supplement manufacturer dealing with the lack of controlled processing infrastructure for marine biomolecules — this project developed innovative cell cultivation at aquaria and mesocosm scales to ensure consistent quality.
Based on available project data, specific pricing or implementation costs are not provided, though the project received an EU contribution of EUR 4,380,450 for development.
The project aims to develop cultivation methods at cell, aquaria, and mesocosm scales, moving toward industrial viability.
Based on available project data, specific licensing terms are not mentioned, but the project focuses on developing new chassis cells and isolation processes.
The project period runs from 2024-01-01 to 2026-12-31, suggesting results will be finalized by the end of 2026.
The project develops 'green downstream processes' specifically designed for the isolation of seaweed and sponge active compounds to fit into production lines.
The consortium is heavily research-oriented with 9 universities and 2 research institutes, but it includes 2 industrial partners and 3 SMEs. This 14% industry ratio indicates the project is primarily in the discovery and validation phase, though the inclusion of SMEs suggests a path toward commercial application in the cosmetic and medical sectors.
Contact the University of Galway regarding marine biotechnology transfer.
Contact SciTransfer to identify licensing opportunities for marine chassis cells.
